Health
Should AstraZeneca Be Your Next Coronavirus Buy? – The Motley Fool
The drugmaker might well win the coronavirus vaccine race. What would that mean for its stock?
With no end in sight for the coronavirus pandemic, the world is seeing a frantic effort to develop a vaccine for the deadly virus. SARS-CoV-2, the coronavirus responsible for the COVID-19 disease, has taken close to 833,000 lives worldwide. Global recorded cases stand at 24 million, with 5.8 million — and more than 180,000 COVID-related deaths — in the U.S. alone.
AstraZeneca (NYSE:AZN), based in Cambridge, U.K., is working with the University of Oxford to develop its vaccine candidate, AZD12…
-
General19 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General21 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Noosa News16 hours agoSerious traffic crash, Noosa – Sunshine Coast
-
Business23 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years